Practice 5 structured short- and long-answer medical questions on Weekly Year 3: Medical Mycology Exam - August 14, 2026 (Sections B & C). Review model answe...
Answer: The most likely group of causative organisms are dermatophytes (e.g., *Trichophyton*, *Microsporum*, *Epidermophyton* species). These keratinophilic fungi cause superficial infections often referred to as tinea corporis (ringworm). The primary diagnostic approach involves microscopic examination of skin scrapings collected from the active border of the lesion. These scrapings are treated with 10-20% potassium hydroxide (KOH) solution to dissolve keratinocytes, allowing visualization of fungal hyphae and arthroconidia. Fungal culture on Sabouraud Dextrose Agar (SDA) can also be performed for definitive species identification and antifungal susceptibility testing if indicated.
Answer: Three common clinical manifestations of *Candida albicans* infection include: 1. Oropharyngeal candidiasis (thrush) 2. Vulvovaginal candidiasis 3. Cutaneous candidiasis (e.g., intertrigo in skin folds, diaper rash) 4. Esophageal candidiasis 5. Onychomycosis (nail infection) Two significant predisposing factors for mucocutaneous candidiasis are: 1. **Antibiotic use**: Disrupts normal bacterial flora, leading to overgrowth of *Candida*. 2. **Diabetes mellitus**: Elevated glucose levels in tissues and secretions, and impaired immune responses. 3. **Immunosuppression**: Conditions like HIV/AIDS, corticosteroid therapy, or other immunosuppressive drugs. 4. **Pregnancy/Oral Contraceptive Use**: Hormonal changes. 5. **Wearing occlusive clothing or dentures**: Creates moist environments.
Answer: The key characteristic that defines dimorphic fungi is their ability to exist in two distinct morphological forms depending on environmental temperature. They typically grow as molds (filamentous form with hyphae) at ambient temperatures (e.g., 25-30°C) and as yeasts (oval, budding cells) at body temperature (e.g., 37°C) or within host tissues. This temperature-dependent dimorphism is crucial for their pathogenicity. Two medically important examples from different geographical regions include: 1. ***Histoplasma capsulatum***: Endemic to the Ohio and Mississippi River valleys in the USA, and parts of Central and South America, Africa, and Asia. 2. ***Coccidioides immitis/posadasii***: Endemic to arid and semi-arid regions of the Southwestern USA (e.g., California, Arizona), Mexico, and South America.
Answer: 1. **Polyenes (e.g., Amphotericin B, Nystatin)**: These drugs directly bind to ergosterol, a sterol unique and essential to the fungal cell membrane (analogous to cholesterol in mammalian cells). This binding creates pores or channels in the membrane, leading to increased permeability, leakage of intracellular ions (e.g., K+) and macromolecules, disruption of cellular homeostasis, and ultimately fungal cell lysis and death. 2. **Azoles (e.g., Fluconazole, Itraconazole, Voriconazole)**: Azoles inhibit the fungal cytochrome P450 enzyme 14-alpha-demethylase, which is critical for the conversion of lanosterol to ergosterol. By blocking this enzyme, azoles prevent the synthesis of ergosterol, causing a depletion of ergosterol in the fungal cell membrane and an accumulation of toxic methylated sterol precursors. This disruption impairs membrane fluidity, enzyme function, and fungal growth (fungistatic effect at typical therapeutic concentrations).
Answer: Opportunistic fungal infections represent a significant cause of morbidity and mortality in immunocompromised patients, with the type of infection often correlating with the specific immune defect. Major opportunistic fungal pathogens include *Candida* species, *Aspergillus* species, *Cryptococcus neoformans*, *Pneumocystis jirovecii*, and the Mucorales. ### **A. *Candida albicans*** **Predisposing Factors:** * **Neutropenia:** Profound and prolonged neutropenia (e.g., in chemotherapy patients, acute leukemia) is a primary risk factor for invasive candidiasis. * **Broad-spectrum Antibiotic Use:** Disrupts the normal bacterial microbiota, leading to *Candida* overgrowth and potential translocation. * **Central Venous Catheters (CVCs):** Serve as a direct portal of entry and a surface for biofilm formation, a leading cause of candidemia. * **Abdominal Surgery or Gastrointestinal Perforation:** Allows translocation of *Candida* from the gut lumen into the bloodstream. * **Diabetes Mellitus:** Impairs host immune function and provides a glucose-rich environment. * **Immunosuppressive Therapy:** Corticosteroids, immunosuppressants in transplant recipients. * **HIV/AIDS:** Predisposes particularly to mucocutaneous candidiasis. **Clinical Presentations:** * **Mucocutaneous Candidiasis:** Common, including oropharyngeal candidiasis (thrush), esophageal candidiasis, vulvovaginal candidiasis, and cutaneous candidiasis (e.g., intertrigo, diaper rash). * **Candidemia:** Bloodstream infection, often catheter-related, which can lead to disseminated infection. * **Disseminated Candidiasis:** Involves multiple organs, with common sites including the liver, spleen, kidneys, eyes (endophthalmitis), and heart (endocarditis). * **Chronic Disseminated Candidiasis (Hepatosplenic Candidiasis):** Occurs in neutropenic patients recovering from chemotherapy, characterized by microabscesses in the liver and spleen. **Key Diagnostic Approaches:** * **Culture:** Blood cultures (sensitivity is variable, especially for non-*albicans* species), cultures from sterile body fluids, or tissue biopsies. * **Microscopy:** KOH preparations for mucocutaneous lesions; Gram stain for detection of yeasts and pseudohyphae in sterile fluids. * **Biomarkers:** (1→3)-β-D-glucan assay (detects a fungal cell wall component, often elevated in invasive candidiasis); T2 Magnetic Resonance (T2MR) assay for direct detection of *Candida* DNA in blood. * **Histopathology:** Biopsy specimens demonstrating yeast cells and pseudohyphae invading tissues. **Therapeutic Approaches:** * **Echinocandins (e.g., Caspofungin, Micafungin):** First-line therapy for moderately severe to severe invasive candidiasis, especially in neutropenic patients, due to their excellent safety profile and efficacy. * **Fluconazole:** Appropriate for less severe infections, step-down therapy, or for susceptible species (e.g., *C. albicans*, *C. parapsilosis*). * **Amphotericin B Formulations:** Reserved for fluconazole-resistant species, critically ill patients, or those intolerant to other agents. * **Catheter Removal:** Crucial for managing catheter-related candidemia. ### **B. *Aspergillus fumigatus*** **Predisposing Factors:** * **Prolonged Neutropenia:** The most significant risk factor, particularly in patients with acute leukemia and hematopoietic stem cell transplant recipients. * **High-dose Corticosteroids:** Impairs macrophage and T-cell function, crucial for anti-Aspergillus immunity. * **Immunosuppression in Solid Organ Transplant Recipients:** Especially lung and heart transplant recipients. * **Chronic Granulomatous Disease (CGD):** A genetic defect in phagocyte oxidative burst, increasing susceptibility. * **Severe Viral Infections:** Such as severe influenza or COVID-19, which can damage lung epithelium and impair immune responses (e.g., COVID-19 Associated Pulmonary Aspergillosis, CAPA). **Clinical Presentations:** * **Invasive Pulmonary Aspergillosis (IPA):** The most common form, characterized by fever, cough, dyspnea, and pleuritic chest pain. CT scans may reveal characteristic signs like the halo sign (early) or air crescent sign (later). * **Tracheobronchial Aspergillosis:** Seen in lung transplant recipients. * **Invasive Sinusitis:** Can spread locally and potentially to the brain. * **Disseminated Aspergillosis:** Spread from the lungs to other organs, most commonly the brain, skin, kidneys, and liver, associated with a very poor prognosis. * **Allergic Bronchopulmonary Aspergillosis (ABPA):** A hypersensitivity reaction in asthmatics or cystic fibrosis patients, not an invasive infection. * **Aspergilloma:** A 'fungus ball' growing in pre-existing lung cavities, which can cause hemoptysis. **Key Diagnostic Approaches:** * **Culture:** From sputum, bronchoalveolar lavage (BAL) fluid, or tissue biopsies. (Sputum cultures often have low yield for IPA). * **Histopathology:** Tissue biopsy showing characteristic septate hyphae with acute-angle branching (typically 45 degrees) invading tissues. * **Biomarkers:** * **Galactomannan Assay:** Detects a polysaccharide cell wall component in serum or BAL fluid (high sensitivity and specificity, especially in neutropenic patients). * **(1→3)-β-D-glucan Assay:** Less specific for *Aspergillus* but generally indicates invasive fungal infection. * **Imaging:** High-resolution Chest CT scan is crucial, revealing nodules, consolidations, and characteristic signs (halo sign, air crescent sign). **Therapeutic Approaches:** * **Voriconazole:** First-line therapy for invasive aspergillosis, demonstrating superior efficacy compared to Amphotericin B. Requires therapeutic drug monitoring due to pharmacokinetic variability. * **Isavuconazole/Posaconazole:** Alternative azoles, particularly for prophylaxis or salvage therapy. * **Lipid Formulations of Amphotericin B:** Used for patients intolerant to azoles or in cases of azole resistance. * **Echinocandins:** Generally used as salvage therapy or in combination with azoles/Amphotericin B in severe cases, but not as monotherapy for IPA. * **Surgical Debridement:** May be necessary for localized infections (e.g., invasive sinusitis, aspergilloma). * **Reduction of Immunosuppression:** If clinically feasible, to aid host immunity. **Conclusion:** Early diagnosis, often relying on a high index of suspicion and judicious use of diagnostic tests (especially biomarkers and imaging), combined with prompt and appropriate antifungal therapy, are paramount for improving outcomes in immunocompromised patients with opportunistic fungal infections.